ECTRIMS 2015 Barcelona
Let's meet ...
Dr Wolf attends the Congress of the European Committee on Treatment and Research in Multiple Sclerosis from 6-10 October 2015 at the Centre de Convencions Internacional in Barcelona.
Dr Wolf co-authored 3 posters:
- F Barkhof, A Belova, K Selmaj, C Wolf, ERW van den Tweel, JJL Oberyé, R Mulder, NP Koper, JA Cohen, on behalf of the GATE Study Group
Switching from branded to generic glatiramer acetate: two-year MRI data from the GATE trial demonstrates continuous efficacy.
P522 (full text).
- H. Wiendl, F. Dahlke, D. Bennett, G. Rosenkranz, C. Wolf, A. Bar-Or.
IL-17 neutralization by subcutaneous CJM112, a fully human anti IL-17A monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis: study design of a phase 2 trial.
P655 (full text).
- JA Cohen, A Belova, F Barkhof, C Wolf, ERW van den Tweel, JJL Oberyé, R Mulder, NP Koper, K Selmaj, on behalf of the GATE Study Group
Switching from branded to generic glatiramer acetate: two-year clinical data from the GATE trial further support the continued efficacy and tolerability of generic glatiramer.
P1050 (full text).